LONDON (AFX) - Provexis PLC said it has entered into a long-term collaboration agreement with Unilever PLC to jointly develop a new concentrated format of its patented Fruitflow heart-health technology for application in Unilever's food product portfolio.

Financial details of the deal were not disclosed.

The partners plan to enter into a global licence arrangement for the technology.

Fruitflow is a patented natural extract from tomato which Provexis said has been shown in human trials to reduce the propensity for aberrant blood clotting that is typically associated with cardiovascular disease and which can lead to heart attack or stroke.

In 2005 the market for heart benefit foods was worth 4 bln usd globally, Provexis added.

Considering the growth potential this share has a target of about 8-10p in the medium tern and is a good buy at current levels

As usual, pls do ur own research.

Blue again! PING

RNS Number : 1486X
Provexis PLC
10 August 2009



10 August 2009




PROVEXIS PLC




('Provexis' or the 'Company')




Recent share price increase




Provexis plc notes the recent movement in its share price. The Board notes that, further to the Company's announcement of 28 May 2009, the final authorisation procedure by the European Commission in relation to Fruitflow, the Company's anti-thrombotic technology, is still under discussion. An update will be provided in due course.




ENQUIRIES




Provexis plc Tel.01753 752 290

Stephen Moon, CEO

Ian Ford, FD




Arbuthnot Tel.020 7012 2000

Tom Griffiths

Richard Johnson

What a day--brilliant we're on our way!!

moneyplus it dont get much better 3p plus tmrw!!!

managed to free up some money in to but not enough

RNS Number : 1886X
Provexis PLC
11 August 2009



11 August 2009

Provexis plc

('Provexis' or the 'Company')




COMMENCEMENT OF CLINICAL TRIAL FOR CROHN'S DISEASE





Provexis plc (PXS.L), the life-science business that discovers, develops and licenses scientifically-proven functional food, medical food and dietary supplement technologies, announces the commencement of a clinical trial for its NSP#3G plantain medical food for Crohns disease patients.

Our results announcement of 9 June 2009 updated the Clinical Trials Authorisation received from the Medicines & Healthcare products Regulatory Agency. We have since successfully completed the necessary pre-trial processes and can now announce a two-centre trial on Crohns disease patients in remission will commence on 18 August 2009. The trial will last for approximately 18 months, with 72 patients taking part.

Crohns disease is an inflammatory disease of the gastrointestinal tract causing a wide variety of symptoms. It affects between 400,000 and 600,000 in North America and estimates of incidence in Northern Europe range from 27 to 48 per 100,000 people. There is no known pharmaceutical or surgical cure for Crohns disease and treatment is restricted to controlling symptoms, maintaining remission and preventing relapse. The Company believes that its medical food technology will successfully maintain remission. The market for Crohns disease treatments is estimated at $1.7bn annually.


With the trial now starting and combined with recently obtained healthy human data, the Company will now commence seeking to identify potential global license or co-development partners to address this substantial market opportunity



Stephen Moon, Chief Executive Officer of Provexis plc, commented:




'Following our recent industry-first European Article 13(5) health claim approval for our Fruitflow anti-thrombotic technology, this further underpins Provexis' capability in developing high quality and scientifically-proven intellectual property. Our new technology addresses an important patient need for a debilitating disease where no effective medical food products for maintaining remission are available currently. Laboratory and human trial work to date has been very promising and we look forward to successful clinical data from this important trial.'







-ends-




For further information please contact:

Stephen Moon, Chief Executive

Provexis plc Tel: 01753 752290




Tom Griffiths/Alasdair Younie Tel: 020 7012 2000

Arbuthnot Securities

was definately worth the wait - almost 5 years - and I'm willing to wait even more - this has a long way to go - we havn't even had final confirmation of EC nor the subsequent commercial agreements that are waiting in the wings though these feel like they are beginning to be priced in. well done everyone who kept the faith and posting updates - your reward is here.

Global, with everthing in the pipeline 10p will be a distant memory soon!!!

It's looking good...think I've been in for as long as 4/5 yrs also and have topped up recently at around 1p mark.... so it's nice to see this coming good... and hopefully a lot more to come !

good on everyone who held on for this. 1 out of 15 shares coming good makes it all worth while!

GN--quite agree I have had about 9 shares go suspended or bust--bb. wlw and various oilies like tom ive and eel! I have every hope this little gem will claw back my losses and more. Great news today and lots more to come.

Currently 14 mil more buys than sells this should be up more. Plus anybody else having problems getting on ad%fn

Yes---overwhelmed perhaps lol! sp holding steady despite all the buys.

14% up take that everyday

3 mil late reported trades angle offloading more held us back poss.

blanche - even 5% would be good...perceptions are becoming distorted....

Some people are talking about takeovers......not sure this makes any sense since the agreements with commercial partners as outlined in news and interims etc are all related to particular fields/markets and only for fruitflow. So coca cola has rights to beverage market excluding mini drinks, the guys selling sirco ( the name slips me) have rights to juices, unilever have/had rights to spreads. So there is no incentive for coke to takeover provexis. it has/will confirm a deal to license the product in a certain niche. DSM Venturing is the division that invests in new tech companies - i do not think they will launch a takeover. Angle have been supporting as start up investors and i presume felt their role was finished since pxs moved to a new phase. unilever seem to have dropped the ball by changing their market strategy.

I believe pxs will grow as an independent Rand D company ( they can recruit whichever staff they need) and continue to license out their intellectual property into niche markets. Coke Danone etc are not interested nor do they want to be involved in pure pharma and are here for the beneficial food market.

UK start-up Provexis is confident the European Commission, in consultation with member states, will issue consumer-friendly wording for its tomato extract blood circulation health claim.

Provexis is the only company to earn a positive article 13.5 opinion so far. Twelve others have failed to impress EFSA scientists for varying reasons including poor trial design and inappropriate claim wording.

http://www.nutraingredients.com/On-your-radar/Health-claims/EU-tomato-extract-health-claim-wording-gets-user-friendly-treatment

Courtesy of rmart on ADVFN:-


rmart - 14 Aug'09 - 11:15 - 7431 of 7503

Press Release
August 2009

Younger generation who turn away from tomatoes
could be at risk of heart disease

A quarter of young people could be missing out on the unique heart health benefits found in tomatoes.

A survey1 commissioned on behalf of Sirco, a new 100% fruit juice with all the goodness of tomatoes without the taste of tomatoes and proven benefits for blood circulation and heart health, has revealed that a staggering quarter (25%) of 18-24s dont eat tomatoes or drink tomato juice at all with three quarters (77%) of all adults saying its because of the taste.

Half (50%) of those young people (those aged 18 to 24) asked only ate tomatoes or drank tomato juice once every few months to once a week. This, when combined with common risk factors, such as smoking, excessive alcohol consumption9, lack of exercise, stress and obesity9, could increase their chance of heart disease.

Sirco, the first and only fruit juice drink proven to benefit blood circulation, developed to offer a much more palatable solution, comes in two new delicious 100% pure fruit juices mixes, Pomegranate/Orange and Blueberry/Apple, both containing a tasteless patented tomato extract, Fruitflow, that has scientifically proven heart and circulation health benefits.

The blood platelet smoothing action of Sirco takes effect from the very first 250ml glass and lasts up to 18 hours.2, 3. Study results also show that the platelet smoothing benefits of Sirco cannot be achieved through consumption of the corresponding amount of tomato juice..

Dr Chris Steele, MBE, resident GP on This Morning, suggests that many people could benefit from Sirco and should discuss it with their GPs; The role of blood clots and blood health in cardiovascular health is less clear to patients than the role of cholesterol, but I would suggest no less important.

More people now recognise that cholesterol furs and causes narrowing of the arteries, but they do not understand that it is the thrombus or blood clot, caused by platelet aggregation (getting sticky) that causes potentially fatal heart attacks and strokes.

With Sirco we have a product that is scientifically proven to help keep your blood healthy, benefit your circulation and so help maintain a healthy heart and cardiovascular system. Recommended to patients as part of a healthy diet and lifestyle, products such as Sirco and cholesterol lowering products can work together in helping to maintain heart health.

The number of young people not eating tomatoes or drinking tomato juice compares starkly with over 55s, of which, only 4% abstain. In fact, each generation consumes less tomatoes than the previous generation with 17% of 25-34 year olds, 15% of 35-44 year olds and 6% of 45-54 year olds abstaining. This represents at least x million people (number to be quoted) who could be at risk of heart disease.

Sirco is available in major retailers such as Waitrose, Holland & Barrett, Ocado and Independent Health food stores, Tree of Life, The Health Store and The Natural Health Company. It is available in 1 litre cartons in two flavours (Blueberry & Apple and Pomegranate & Orange), and retails between 1.89 and 2.59.

More information is available from www.sircoheart.com.

-ENDS-

rmart - 14 Aug'09 - 11:16 - 7432 of 7503

Notes to Editors:
Sirco does not contain artificial sweeteners, preservatives, colours or flavours and is naturally cholesterol and salt free.
One 250ml serving of Sirco contains 3g of Fruitflow (the recommended daily consumption).
Sirco is a one-a-day drink which works with your body on the day you drink it.
A 250ml serving of Sirco provides you with one portion of your recommended five fruits a day.
As Sirco is designed for adults it is not recommended for children.
There is no evidence that drinking more than the recommended dose of Sirco, as with eating too many tomatoes, would be harmful.
Tomatoes are proven to contain ingredients with potent antiplatelet properties that help keep blood platelets smooth so they dont clump together, and so blood flows more freely.

Fruitflow
Antiplatelet therapy has become a widely accepted therapeutic intervention to reduce the rate of coronary events and stroke in specific patient groups. However for patients at lower coronary risk, there is still much debate around the impact of undesirable effects vs benefits for recommending the use of antiplatelet therapies such as aspirin.8 As would be expected for a heart health drink, no side effects have been reported in trials to date.2, 3 Sirco has also shown no effect on the natural clotting process which occurs with injury.2, 3

In 2001, having already published data that showed tomatoes contain ingredients with potent antiplatelet properties,4, 5 a team of scientists led by Professor Asim Duttaroy at the Rowett Institute of Health & Nutrition, University of Aberdeen formulated an extract of ripe tomatoes which delivered these effects in vivo. Four years of further clinical research by Provexis have shown that the extract, Fruitflow, has multiple modes of action in vitro and in vivo, and works against a range of physiological mediators of platelet aggregation including collagen, thrombin, ADP and arachidonic acid.2, 3

Platelet function in response to ADP or collagen was altered in 97% of trial subjects after consumption of fruitflow.2, 3 While the average response in studies was in the range 8-23% inhibition of baseline platelet aggregation, a subset of subjects showed a higher response (in the range 20-35% inhibition).2, 3 These individuals had higher than average plasma concentrations of two emerging markers of cardiovascular risk: C-reactive protein and homocysteine, both of which have been reported to affect platelet function.6, 7 It would appear, therefore, that the individuals who show the greatest response are those who could potentially derive greater benefit from a dietary antiplatelet agent.

have just noticed that the header of this thread has come around again - expect it is more true this time....

"Provexis Buy at 3.25p - Target 8p"

looking for 10p